Research presented at the European Society of Cardiology (ESC) Congress 2025 indicated that *olezarsen*, marketed as *Tryngolza*, effectively normalizes triglyceride (TG) levels in over...
Cytokinetics has announced that its cardiac myosin inhibitor, aficamten, may redefine the standard of care for patients with heart muscle disorders. This revelation came...